Results 131 to 140 of about 54,904 (251)
Nanobody molecules, derived from heavy‐chain only antibodies in camelids, represent the next generation of biotherapeutics. In addition to low immunogenicity, high stability, and potency, their single‐domain format facilitates the construction of ...
Aaron R. J. Hutton +10 more
doaj +1 more source
The science of monetary policy: A new Keynesian perspective [PDF]
This paper reviews the recent literature on monetary policy rules. We exposit the monetary policy design problem within a simple baseline theoretical framework. We then consider the implications of adding various real world complications.
Jordi Galí +2 more
core
Separation, purification and overexpression of anti-MUC1 nanobody from VHH phagemid library [PDF]
Elham Sadeqzadeh +3 more
openalex +1 more source
Stanislavsky's Threshold: Tracking a Historical Paradigm Shift in Acting [PDF]
Spatz, Ben
core +1 more source
Do Macroeconomic Announcements Cause Asymmetric Volatility [PDF]
multivariate GARCH;volatility;macroeconomics;garch models;stock markets;bond ...
Goeij, P. C. de, Marquering, W.
core +1 more source
Long-term safety and efficacy of anti-TNF multivalent VHH antibodies ozoralizumab in patients with rheumatoid arthritis [PDF]
Yoshiya Tanaka +4 more
openalex +1 more source
Biparatopic anti-PCSK9 antibody enhances the LDL-uptake in HepG2 cells
Proprotein convertase subtilisin/kexin type 9 (PCSK9) has emerged as a promising therapeutic target to reduce lipids. In 2020, we reported a chimeric camelid-human heavy chain antibody VHH-B11-Fc targeting PCSK9.
Xinyang Li +14 more
doaj +1 more source
Sticky price models of the business cycle: can the contract multiplier solve the persistence problem? [PDF]
We construct a quantitative equilibrium model with price setting and use it to ask whether with staggered price setting monetary shocks can generate business cycle fluctuations.
Ellen R. McGrattan +2 more
core

